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ABSTRACT:
Ewing sarcoma occurs in children, adolescents and young adults. High STAT3 
levels have been reported in approximately 50% of patients with Ewing sarcoma, and 
may be important in tumorigenesis. Protein tyrosine phosphatase delta (PTPRD) is a 
tumor suppressor that inhibits STAT3 activation. To date, while somatic mutations in 
PTPRD have been reported in diverse tumors, germline mutations of PTPRD have not 
been investigated in Ewing sarcoma or other cancers. We identified a novel germline 
mutation in the PTPRD gene in three of eight patients (37.5%) with metastatic Ewing 
sarcoma. Although the functional impact in two of the patients is unclear, in one of 
them the aberration was annotated as a W775stop germline mutation, and would be 
expected to lead to gene truncation and, hence, loss of the STAT3 dephosphorylation 
function of PTPRD. Since STAT3 is phosphorylated after being recruited to the insulin 
growth factor receptor (IGF-1R), suppression of IGF-1R could attenuate the enhanced 
STAT3 activation expected in the presence of PTPRD mutations. Of interest, two of 
three patients with germline PTPRD mutations achieved durable complete responses 
following treatment with IGF-1R monoclonal antibody-based therapies. Our pilot data 
suggest that PTPRD germline mutations may play a role in the development of Ewing 
sarcoma, a disease of young people, and their presence may have implications for 
therapy.
INTRODUCTION
Germline mutations occur in several cancer-related 
genes including, but not limited to, BRCA1, BRCA2, 
RB1 and TP53.[1-4] Patients with these mutations often 
develop tumors at a young age.  Ewing sarcoma is a 
malignant, small, round blue-cell tumor that primarily 
occurs in children, adolescents and young adults. [5, 6] It 
is associated with a somatic translocation of chromosome 
22, which typically generates a fusion protein product 
designated as EWS-FLI1.[7]   
Approximately 50% of patients with Ewing 
sarcoma also express activated/phosphorylated signal 
transducer and activator of transcription 3 (STAT3).[8] 
STAT3 is known to drive pathways regulating normal cell 
growth, which result in tumorigenesis when dysregulated.
[9] Protein tyrosine phosphatase delta (PTPRD), a 
tumor suppressor belonging to the protein tyrosine 
phosphatase (PTP) family[10], plays an essential role in 
dephosphorylating STAT3.[11] Genetic aberrations of 
PTPRD are associated with a poor prognosis in malignant 
tumors.[11, 12] Mutations in PTPRD have been reported 
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in approximately 13% of head and neck squamous cell 
carcinoma [11], 12% of melanoma [13], and in a small 
subset of various other malignancies.[11] However, 
germline mutations of PTPRD have not been previously 
described. 
Here we report three of eight patients (37.5%) 
with metastatic Ewing sarcoma who harbored germline 
mutations in the PTPRD gene. Using next-generation 
sequencing (NGS), two germline mutations were found 
in one patient, including one leading to truncation and 
subsequent loss of function of the PTPRD suppressor. Of 
interest, two of these three patients achieved a complete 
response (CR) following insulin-like growth factor 1 
receptor (IGF-1R) inhibitor-based therapy. Because 
phosphorylated STAT3 is frequently upregulated in Ewing 
sarcoma [8] and PTPRD dephosphorylates STAT3, the 
role of germline and somatic PTPRD mutations in Ewing 
sarcoma as well as the implications for IGF-1R targeted 
therapy warrant exploration.
RESULTS
A total of eight patients diagnosed with advanced/
metastatic Ewing sarcoma with available PBMCs who 
had been referred to the CCTT and/or Department of 
Pediatrics at MD Anderson were analyzed. The median 
age at diagnosis was 19.5 years (range, 13 to 34 years). 
All patients developed metastatic disease between 0 and 7 
years after initial diagnosis (Table 1).    
Of the eight patients with Ewing sarcoma, three 
(37.5%) had germline mutations in the PTPRD gene. 
Patient 1 (Table 1; age 24 at diagnosis) had mutational 
analysis of 182 cancer-related genomic alterations in 
formalin-fixed paraffin-embedded tumor tissue performed 
using a Clinical Laboratory Improvement Amendment 
approved Foundation One platform. Simultaneously, 
DNA extracted from tumor tissue and PBMCs from the 
same patient were analyzed independently with next-
generation whole exome sequencing in the MD Anderson 
Core Laboratory using the SOLiD platform. A PTPRD 
mutation annotated as a W775stop germline mutation was 
found in both the patient’s tumor and PBMCs (Figure 1). 
The PTPRD mutation was confirmed by polymerase chain 
reaction (PCR)-based Sanger sequencing in genomic DNA 
derived from tumor and PBMCs. The W775stop germline 
mutation is located in the extracellular fibronectin 
type III (FN3) region (Figure 1).[10] The mutation of 
tryptophan to a stop codon results in the truncation of all 
transmembrane and intracellular domains, which leads to 
partial loss of the dephosphorylation function of PTPRD. 
Because PTPRD functions as a STAT3 phosphorylation 
Figure 1: IGF-1R is one of the mediators of STAT3 activity. STAT3 is phosphorylated by JAK2, after being recruited to IGF-1R 
by RACK1. After STAT3’s phosphorylation by JAK2, PTPRD normally dephosphorylates STAT3. In the presence of a truncated PTPRD, 
STAT3 would remain phosphorylated.
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suppressor, it is plausible that partial loss of PTPRD can 
lead to increased STAT3 phosphorylation.[11] In addition, 
NGS revealed a V253I germline mutation located in the 
third immunoglobulin (Ig)-like domain of the receptor 
protein tyrosine phosphatase (RPTP)-F region, also known 
as LAR, within the extracellular domain (Figure 1) [10]. 
The impact of this mutation is, however, unclear. Patient 
1 had durable CRs resulting from IGF-1R inhibitor-based 
therapies (Figure 2).[14, 17-20] 
PBMCs from an additional seven patients (2 to 8, 
Table 1) with advanced Ewing sarcoma were analyzed 
for PTPRD germline mutations in all 35 exons (exons 
11-45, ENST00000381196) using Sanger sequencing, as 
previously described.[11] Among these seven patients, 
five had wild-type PTPRD and two had PTPRD germline 
mutations: T781A and R995C. The tumor tissues from 
these two patients were not available for testing. A second 
patient with a PTPRD mutation (Patient 5, Table 1) also 
attained a CR on IGF-1R inhibitor-based therapy. 
DISCUSSION
We identified germline PTPRD mutations in three 
(37.5%) of eight patients with advanced/metastatic Ewing 
sarcoma. The first patient had two mutations (Table 1). 
The PTPRD W775stop germline mutation is expected 
to express truncated PTPRD protein, leading to loss of 
function; however, it has not previously been reported in 
the Exome Sequencing Project (ESP) [21] and Catalogue 
of Somatic Mutations in Cancer (COSMIC) databases [22] 
in the general population or in cancer patients (Figure 1). 
The W775stop germline mutation can lead to the truncation 
of all transmembrane and intracellular domains, which can 
Table 1: Patients with Ewing sarcoma tested for germline mutations in PTPRD and 






Best RECIST response 
to IGF-1R inhibitor 
monotherapy (PFS)
Best RECIST response to 
IGF-1R+mTOR inhibitor 
(PFS)
1 24 V253I, W775stop 6 months CR, -100%  (3 years) CR, -100%  (2 years)
2 22 T781A 0 Not treated PD, +21% 
3 33 Wild-type 7 years Not treated SD, -27%  (16+ months)
4 18 Wild-type 2 years Not treated SD, -23% (20 months)
5 13 R995C 1 years Not treated CR, -100%  (28 months)
6 21 Wild-type 0 Not treated PD, -42%, new lesion
7 13 Wild-type 0 Not treated SD, -14%  (4.5 months)
8 13 Wild-type 0   Not treated Not treated 
Abbreviations: RECIST, response evaluation criteria in solid tumors; IGF-1R, insulin-like growth factor receptor 1; 
CR, complete response; PD, progressive disease; SD, stable disease
Figure 2: Patient 1 demonstrated a durable complete response to therapy with an IGF-1R inhibitor.
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putatively result in partial loss of the dephosphorylation 
function of PTPRD.  Because PTPRD serves to suppress 
STAT3 phosphorylation [11], partial loss of PTPRD can 
possibly lead to increased STAT3 phosphorylation, which 
has been reported in approximately 50% of patients with 
Ewing sarcoma.[8] Patient 1 also had a PTPRD V253I 
germline mutation located within the extracellular domain 
coding region; its functional consequences are unclear 
(Figure 1).[10]  In another two patients, we identified 
germline mutations T781A and R995C, which are single 
nucleotide polymorphisms of the PTPRD suppressor that 
have been reported in a small subset (2.2% and 7.4%, 
respectively) of the general population [21], but whose 
functional impact is unclear.
Two of three patients with germline PTPRD 
mutations attained a CR in response to therapies with a 
IGF-1R monoclonal antibody and or a combination of an 
IGF-1R monoclonal antibody and the mTOR inhibitor 
temsirolimus. IGF-1R is one of the mediators of STAT3 
activity. STAT3 is phosphorylated by JAK2, after being 
recruited to the IGF-1R by RACK1 (Figure 1).[23] After 
STAT3 phosphorylation by JAK2, PTPRD normally serves 
to dephosphorylate STAT3.   In the presence of truncated 
PTPRD, STAT3 would remain phosphorylated.  However, 
based on the biology described, an IGF-1R inhibitor 
might interfere with the initial phosphorylation of STAT3, 
perhaps explaining the response to IGF-1R inhibition in 
these patients.  
Somatic PTPRD mutations have been identified 
in a small subset of patients with cancer types such as 
glioblastoma multiforme, melanoma, squamous cell 
carcinoma of the head and neck, and others.[11, 13] 
To date, germline mutations of PTPRD have not been 
described in Ewing sarcoma. Our sample size is small, 
and the functional consequences of the mutations have 
not been fully elucidated; therefore, our findings should be 
interpreted with caution.   However, the role of germline 
PTPRD mutations in predisposition to Ewing sarcoma, a 
disease of children, adolescents, and young adults, and the 
implications of these mutations for therapy with IGF-1R 
and STAT3 inhibitors warrants further investigation.
PATIENTS AND METHODS
Patients
We reviewed the electronic medical records of 
eight patients with advanced/metastatic Ewing sarcoma 
referred to the Clinical Center for Targeted Therapy 
(CCTT) at The University of Texas MD Anderson Cancer 
Center (MD Anderson) who had available peripheral 
blood mononuclear cells (PBMCs) and, in some cases, 
tumor tissue. Data were collected from transcribed notes, 
radiology films and reports in the electronic medical 
record and other source documentation. Registering 
patients in the database, clinical, pathologic, laboratory 
and pathology assessment were performed at MD 
Anderson. The study and all treatments were conducted 
in accordance with the guidelines of the MD Anderson 
Institutional Review Board. 
Molecular analysis
Targeted NGS of tumor tissue was performed in a 
Clinical Laboratory Improvement Amendment-approved 
laboratory at Foundation Medicine (Cambridge, MA). 
Genomic libraries were captured for 3,230 exons in 182 
cancer-related genes plus 37 introns from 14 genes that 
are often rearranged in cancer and sequenced to an average 
median depth of 734X with 99% of bases covered >100X. 
Whole exome sequencing of tumor and PBMC 
samples was performed using an Applied Biosystems 
5500XL SOLiD Next-Generation Sequencing platform 
(Life Technologies, Carlsbad, CA) in the MD Anderson 
Core laboratory. The 5500XL SOLiD system generates 
300 GB of mappable sequence tags in a single run. This 
level of data throughput enables 30X coverage of the 
human genome with high accuracy and depth, facilitating 
detection of rare somatic mutations, insertions and 
deletions in patient samples.
Sanger sequencing of tumor tissue and PBMCs used 
to identify PTPRD mutations in all 35 exon (exons 11-45, 
ENST00000381196) was done as previously described.
[11] 
Treatment
Patients were enrolled in clinical trials with a single-
agent IGF-1R monoclonal antibody or a combination of a 
monoclonal IGF-1R monoclonal antibody and the mTOR 
inhibitor temsirolimus.[14, 15] Treatment was carried 
out according to the specific requisites in these treatment 
protocols and continued until disease progression or 
unacceptable toxicity occurred. 
Assessments, including history, physical 
examination, and laboratory evaluations, were performed 
as specified in each protocol, typically before the initiation 
of therapy, weekly during the first cycle, and then, at a 
minimum, at the beginning of each new treatment cycle. 
Response was assessed from computed tomography 
(CT) scans and/or magnetic resonance imaging (MRI) 
at baseline before treatment initiation and then every 
2 cycles (8 weeks). All radiographs were read in the 
Department of Radiology at MD Anderson and reviewed 
in the Department of Investigational Cancer Therapeutics 
tumor measurement clinic. Responses were categorized 
per RECIST criteria.[16] In brief, a CR was defined as 
the disappearance of all measurable and non-measurable 
disease; partial response (PR) was defined as at least a 30% 
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decrease in the sum of the longest diameter of measurable 
target lesions; progressive disease (PD) was defined as at 
least a 20% increase in the sum of the longest diameter 
of measurable target lesions, or unequivocal progression 
of a non-target lesion, or the appearance of a new lesion; 
and stable disease (SD) was defined as neither sufficient 
shrinkage to qualify as a PR nor an increase sufficient to 
qualify as PD. 
Statistical analysis
There was no formal statistical analysis; however, 
progression-free survival (PFS) was defined as the time 
interval from the start of therapy to the first observation 
of disease progression or death, whichever occurred first. 
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